FDA APPROVAL OF
TIL THERAPY
In February 2024, lifileucel became the first TIL therapy approved anywhere in the world. Here is what it means โ and what it does not mean โ for patients.
analyticsAt a Glance
- check_circleLifileucel (Amtagvi) received FDA approval in February 2024 โ the first approved TIL therapy
- check_circleApproved for unresectable or metastatic melanoma after prior PD-1 inhibitor therapy
- check_circleManufacturing requires 22 days โ tumour must be surgically removed for cell extraction
- check_circleFDA approval has opened the door for TIL programmes globally and increased trial access
What Exactly Was Approved
Lifileucel (Amtagvi) is approved for adults with unresectable or metastatic melanoma who have already received a PD-1 blocking antibody and, where relevant, targeted therapy for BRAF-mutated disease. It is not a first-line treatment. It is not approved for other cancer types yet.
โBefore February 2024, no cell therapy based on non-engineered immune cells had ever been commercially approved anywhere in the world.โ
The Approval in Numbers
- Feb 2024Approval DateFirst TIL therapy approved anywhere globally โ a regulatory milestone for adoptive cell therapy.
- ~31.5%Pivotal Trial ORRObjective response rate in the C-144-01 trial โ in heavily pre-treated patients who failed prior immunotherapy.
- C-144-01Pivotal Trial NameSingle-arm, open-label trial that formed the basis of the FDA approval for lifileucel.
Why This Approval Matters Beyond Melanoma
Lifileucel validation TIL therapy as manufacturable, regulatable, and commercially viable. It created a precedent, triggered insurer coverage conversations, and set a framework that other TIL products and cancer indications can build toward. For cervical cancer, lung cancer, and other solid tumors โ this approval is the foundation they are building on.
Regulatory Status Outside the United States
| Region / Country | Status |
|---|---|
| United States | Full FDA approval (Feb 2024) โ commercially available through certified centers |
| European Union | EMA review underway โ TIL products under regulatory assessment |
| Israel | Active TIL programs with own regulatory pathway |
| Australia | Active TIL therapy programs; access through specialist centers |
| Asia (China, South Korea) | Active clinical trials โ regulatory approval pathways in development |
Frequently Asked Questions
FDA Approval and TIL Therapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Wondering If Approved TIL Therapy Applies to Your Situation?
Upload your medical reports for a specialist evaluation. We will assess your eligibility for lifileucel or active trial programs based on your specific cancer and treatment history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.